Principal Investigator
Enrollment Status
Clinical Trial ID
Clinical Trial Summary
The purpose of this randomized study is to assess safety and effectiveness of BMS-986263 in
adults with compensated cirrhosis (chronic liver disease) from nonalcoholic steatohepatitis
(fatty liver disease) (NASH).
Phase
Phase 2
Funding Agency/Sponsor
Industry
Disease
Non-Alcoholic Steatohepatitis (NASH)
Enrollment Eligibility
Inclusion Criteria:
- Participants with liver biopsy fibrosis score stage 4 (NASH CRN) performed within 12
months
- Men and women must agree to follow methods of contraception
Exclusion Criteria:
- Worsening liver disease or any disease might compromise participant safety in the
opinion of the investigator
- Known immunocompromised status or any disease or condition which might compromise
participant safety
- Prior exposure to BMS-986263
- Clinically relevant abnormal physical examination, vital signs, ECG, or clinical
laboratory tests
- Hepatic decompensation
Other protocol-defined inclusion/exclusion criteria apply